

### AMENDMENTS TO THE CLAIMS

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing. This listing of claims will replace all prior versions and listings of claims in the application:

1-27. (Canceled).

28. (Currently Amended) An oligonucleotide, comprising: 5'-TGACGTT-3', 5'TGACGTC3' or 5'-AACGTT-3', 8-40 nucleotides in length, ~~and having at least one~~ wherein each internucleotide linkage has a phosphate backbone modification, wherein the phosphate backbone modification is a phosphorothioate.

29. (Currently Amended) An oligonucleotide, comprising: 5'-TGACGTT-3', 5'TGACGTC3' or 5'-AACGTT-3', 8-40 nucleotides in length, and having at least one phosphate backbone modification ~~The oligonucleotide of claim 28,~~ wherein the oligonucleotide is linked to a nucleic acid delivery complex.

30. (Withdrawn) The oligonucleotide of claim 29, wherein the oligonucleotide is ionically linked to or encapsulated in the nucleic acid delivery complex.

31. (Previously Presented) The oligonucleotide of claim 29, wherein the oligonucleotide is covalently linked to the nucleic acid delivery complex.

32. (Previously Presented) The oligonucleotide of claim 29, wherein the nucleic acid delivery complex is a cationic lipid.

33. (Previously Presented) The oligonucleotide of claim 29, wherein the nucleic acid delivery complex is a sterol.

34. (Withdrawn) The oligonucleotide of claim 28, wherein the oligonucleotide comprises 5'-TCAACGTT-3'

35. (Canceled).

36. (Previously Presented) A composition comprising the oligonucleotide of claim 28 and a pharmaceutically acceptable carrier.